Angola Pharmaceuticals & Healthcare Report

Published 05 August 2015

  • 60 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
$1,295.00
Angola Pharmaceuticals & Healthcare Report

BMI View: Growth in Angola's healthcare sector will remain subdued over the near term as lower oil prices persist. A consequence of the oil price crash has seen a sizeable cut in the much-needed government funding for the healthcare sector following the revised state budget in February 2015. The funding cuts and weak consumer purchasing power amid the economic slowdown will result in increasingly unfavourable conditions for multinational pharmaceutical companies.

Headline Expenditure Forecasts

  • Pharmaceuticals: AOA32.09bn (USD326mn) in 2014 to AOA34.25bn (USD302mn) in 2015; +6.7% in local currency and -7.4% in US dollar terms. Forecast revised downwards from last quarter.

  • Healthcare: AOA514.17bn (USD5.22bn) in 2014 to AOA494.91bn (USD4.36bn) in 2015; -3.7% in local currency and -16.5% in US dollar terms. Forecast revised downwards from last quarter.

Risk/Reward Index

Angola's Pharmaceutical Risk/Reward Index (RRI) score for Q415 is 26.0, just lower than Nigeria (26.8). It falls three places from last quarter's ranking, making it the least attractive pharmaceutical market of the 31 countries in the Middle East and Africa region.

Key Trends And Developments

June 2015

The first Chinese-funded private hospital, Zhong Yan Hospital, was opened in the Zango district of Luanda in Angola, reports allAfrica. The USD10mn hospital was financed by the China-based Zhong Xing Construction Company. The hospital was inaugurated by Angolan Minister of Health Jose Van Dunem, Governor of Luanda Graciano Domingos, other Angolan government officials and representatives of the Chinese Chamber of Commerce in Angola. Currently, the hospital has 87 beds for inpatients and more than 100 doctors and nurses from China, Cuba and Angola. The hospital is expected to reduce the strains on Angolan health services caused by a fast growing population.

Angolan Health Minister Jose Van-Dunem has promised to pay special attention to those in the country suffering from diabetes. The...

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Operational Risk
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Angola 2011-2019)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Angola 2011-2019)
19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Angola 2011-2019)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Angola 2011-2019)
20
Key Risks To BMI's Forecast Scenario
21
Macroeconomic Forecasts
22
Economic Analysis
22
Table: Economic Activity (Angola 2010-2019)
25
Industry Risk Reward Ratings
26
Middle East and Africa Risk/Reward Index - Q4 2015
26
Angola Risk/Reward Index
33
Rewards
33
Risks
34
Market Overview
35
Industry Trends And Developments
36
Epidemiology
36
Clinical Trials
40
Regulatory Development
41
Regulatory Developments
41
Intellectual Property Issues
42
Pricing Regime
42
Competitive Landscape
44
Company Developments
45
Company Profile
46
Nova Angom-dica
46
Demographic Forecast
48
Table: Population Headline Indicators (Angola 1990-2025)
49
Table: Key Population Ratios (Angola 1990-2025)
49
Table: Urban/Rural Population & Life Expectancy (Angola 1990-2025)
50
Table: Population By Age Group (Angola 1990-2025)
50
Table: Population By Age Group % (Angola 1990-2025)
51
Glossary
53
Methodology
55
Pharmaceutical Expenditure Forecast Model
55
Healthcare Expenditure Forecast Model
55
Notes On Methodology
56
Risk/Reward Index Methodology
57
Index Overview
58
Table: Pharmaceutical Risk/Reward Index Indicators
58
Indicator Weightings
59

The Angola Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Angola Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Angola pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Angola, to test other views - a key input for successful budgeting and strategic business planning in the Angolan pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Angolan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Angola.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%